Pharmabiz

QR678 notes 30% hair regrowth without drugs as scientists discover reactivation of hair stem cells

QR678, a clinically developed, non-surgical hair regeneration therapy platform based on growth factor science and regenerative dermatology has noted that regenerative approaches deliver up to 3x ...
Pharmabiz

HOSMAC spearheads north Maharashtra’s project management for Tapanbhai Patel Memorial Hospital in Shirpur

HOSMAC spearheads north Maharashtra’s project management for Tapanbhai Patel Memorial Hospital in Shirpur: Our Bureau, Bengaluru Tuesday, May 5, 2026, 14:30 Hrs [IST] HOSMAC, As ...
Pharmabiz

Amgen to invest an additional $300 million in its US manufacturing network to advance US-based production capacity

Amgen to invest an additional $300 million in its US manufacturing network to advance US-based production capacity: Thousand Oaks, California Tuesday, May 5, 2026, 14:00 Hrs [IST] ...
Pharmabiz

Lupin receives US FDA approval for glycerol phenylbutyrate oral liquid

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Applications for glycerol ...
Pharmabiz

AiMeD welcomes UP Govt's integrated medical research application system

AiMeD welcomes UP Govt's integrated medical research application system: Our Bureau, New Delhi Tuesday, May 5, 2026, 13:45 ...
Pharmabiz

Evotec nominates first preclinical development candidate in dermatology collaboration with Almirall

Evotec SE, a life science company that is pioneering the future of drug discovery and development, announced the nomination of a small molecule preclinical development candidate (PDC) from its ...
Pharmabiz

Pharma Eurasia 2026 to open new business opportunities in Tashkent

The global pharmaceutical industry will converge in Tashkent, Uzbekistan, between May 20 and 22, 2026 for Pharma Eurasia 2026, an international exhibition and summit aimed at strengthening ...
Pharmabiz

Australia TGA approves Specialised Therapeutics’ Niktimvo for the treatment of chronic graft-versus-host disease

Australia TGA approves Specialised Therapeutics’ Niktimvo for the treatment of chronic graft-versus-host disease: Singapore Tuesday, May 5, 2026, 12:00 Hrs [IST] Independent bio ...
Pharmabiz

Neurocrine Biosciences initiates phase 1 study of NBIP-'2118, a corticotropin-releasing factor type 2 receptor agonist to treat obesity

Neurocrine Biosciences initiates phase 1 study of NBIP-'2118, a corticotropin-releasing factor type 2 receptor agonist to treat obesity: San Diego Tuesday, May 5, 2026, 10:00 Hrs ...
Pharmabiz

Olympus inks global distribution agreement with EndoRobotics, adds robot-assisted technologies to EndoTherapy portfolio

Olympus inks global distribution agreement with EndoRobotics, adds robot-assisted technologies to EndoTherapy portfolio: Tokyo Tuesday, May 5, 2026, 11:00 Hrs [IST] Olympus Corpor ...
Pharmabiz

UCB to buy clinical-stage biotech company, Candid Therapeuticsfor US$ 2.2 billion

UCB to buy clinical-stage biotech company, Candid Therapeuticsfor US$ 2.2 billion: Brussels, Belgium Tuesday, May 5, 2026, 09:00 Hrs [IST] UCB, a global biopharmaceutical company, ...
Pharmabiz

AI and evidence-based research take centrestage at IPC workshop to enhance scientific publishing

AI and evidence-based research take centrestage at IPC workshop to enhance scientific publishing: Shardul Nautiyal, Mumbai Tuesday, May 5, 2026, 08:00 Hrs [IST] A two-day workshop ...